VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESGO 2021 | Immune checkpoint inhibitors in ovarian cancer

Eric Pujade-Lauraine • 24 Oct 2021
ESGO 2021
Gynecological Cancer Ovarian Cancer
Immuno-Oncology

Eric Pujade-Lauraine, MD, PhD, Hôpital Hôtel-Dieu, Paris, France, outlines the use of immunotherapy in ovarian cancer, the PD1/PD-L1 pathway, as well as novel targets for therapy. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.

More from Eric Pujade-Lauraine

1:06
Improving immunotherapy outcomes in ovarian cancer
Eric Pujade-Lauraine • 24 Oct 2021
2:50
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
Eric Pujade-Lauraine • 26 Sep 2015
3:05
Results from the JAVELIN Ovarian 200 biomarker analysis
Eric Pujade-Lauraine • 24 Oct 2021

Related Videos

0:50
Combinatorial PARPi therapies in advanced endometrial cancer
Benoit You • 11 Apr 2022
2:01
ENDOLA: olaparib, metronomic cyclophosphamide and metformin in advanced endometrial cancer
Benoit You • 11 Apr 2022
0:49
Research priorities for metastatic endometrial cancer
Benoit You • 11 Apr 2022
1:47
Advances in precision therapy for ovarian cancer
Don Dizon • 26 Feb 2022
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals